Total Payments
$7,918
2024 Payments
$1,351
Companies
55
Transactions
478
Medicare Patients
5,910
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$7,907 (99.9%)
Education$10.62 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,907 | 475 | 99.9% |
| Education | $10.62 | 3 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $1,011 | 62 | $0 (2024) |
| Lilly USA, LLC | $838.43 | 54 | $0 (2024) |
| ABBVIE INC. | $760.67 | 57 | $0 (2024) |
| Novo Nordisk Inc | $604.77 | 41 | $0 (2024) |
| Abbott Laboratories | $371.37 | 17 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $342.72 | 19 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $275.42 | 20 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $264.92 | 13 | $0 (2022) |
| Avanir Pharmaceuticals, Inc. | $256.25 | 13 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $250.39 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,351 | 74 | Lilly USA, LLC ($203.55) |
| 2023 | $1,314 | 74 | ABBVIE INC. ($255.54) |
| 2022 | $1,011 | 63 | Lilly USA, LLC ($228.13) |
| 2021 | $1,371 | 92 | GlaxoSmithKline, LLC. ($216.72) |
| 2020 | $1,187 | 71 | GlaxoSmithKline, LLC. ($313.32) |
| 2019 | $683.42 | 42 | GlaxoSmithKline, LLC. ($157.16) |
| 2018 | $417.78 | 24 | Novartis Pharmaceuticals Corporation ($76.49) |
| 2017 | $581.99 | 38 | Boehringer Ingelheim Pharmaceuticals, Inc. ($128.16) |
All Payment Transactions
478 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: NEUROSCIENCE | ||||||
| 11/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: DIABETES | ||||||
| 11/24/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/18/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/11/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.40 | General |
| Category: Diabetes | ||||||
| 10/21/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.93 | General |
| Category: Cardio-renal | ||||||
| 10/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.47 | General |
| Category: NEUROSCIENCE | ||||||
| 09/24/2024 | Philips North America LLC | (CK7) Extended Holter (Device) | Food and Beverage | Cash or cash equivalent | $25.22 | General |
| Category: Medical Device | ||||||
| 09/20/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $20.10 | General |
| Category: Cardio-renal | ||||||
| 09/16/2024 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: NEUROLOGY | ||||||
| 09/16/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.02 | General |
| Category: NEUROSCIENCE | ||||||
| 09/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.83 | General |
| 09/06/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $10.20 | General |
| Category: Diabetes | ||||||
| 08/30/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Biological | ||||||
| 08/29/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $14.52 | General |
| Category: Oncology | ||||||
| 08/27/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/26/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: Diabetes | ||||||
| 08/23/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Diabetes | ||||||
| 08/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.62 | General |
| Category: NEUROSCIENCE | ||||||
| 08/19/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $19.27 | General |
| Category: NEUROSCIENCE | ||||||
| 08/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Cardio-renal | ||||||
| 08/06/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,465 | 5,969 | $944,870 | $325,922 |
| 2022 | 28 | 1,722 | 20,001 | $922,588 | $318,540 |
| 2021 | 26 | 1,250 | 21,940 | $472,573 | $255,702 |
| 2020 | 26 | 1,473 | 20,419 | $573,408 | $280,175 |
Total Patients
5,910
Total Services
68,329
Medicare Billing
$1.2M
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 61 | 1,223 | $335,650 | $110,263 | 32.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 226 | 671 | $172,775 | $57,051 | 33.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 223 | 829 | $82,905 | $48,567 | 58.6% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 116 | 583 | $128,140 | $43,112 | 33.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 53 | 277 | $53,376 | $16,770 | 31.4% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 53 | 61 | $10,065 | $7,891 | 78.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 48 | 54 | $28,620 | $7,058 | 24.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 55 | 55 | $24,546 | $6,510 | 26.5% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 45 | 45 | $13,500 | $6,168 | 45.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 49 | 54 | $15,675 | $4,708 | 30.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 35 | $12,300 | $4,051 | 32.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 98 | 405 | $20,250 | $3,933 | 19.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 28 | 28 | $11,282 | $3,380 | 30.0% |
| G0180 | Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 2023 | 49 | 87 | $15,569 | $3,093 | 19.9% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 30 | 30 | $1,500 | $951.60 | 63.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 31 | 31 | $1,550 | $898.69 | 58.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 12 | $1,224 | $453.35 | 37.0% |
| 81002 | Urinalysis, manual test | Office | 2023 | 72 | 98 | $1,960 | $334.18 | 17.1% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 12 | 13 | $708.63 | $183.92 | 26.0% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 30 | 146 | $2,190 | $152.40 | 7.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 15 | 15 | $1,200 | $149.94 | 12.5% |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | Office | 2023 | 39 | 280 | $2,800 | $117.86 | 4.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 69 | 777 | $3,885 | $70.81 | 1.8% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 24 | 160 | $3,200 | $52.89 | 1.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 77 | 1,236 | $303,056 | $96,741 | 31.9% |
About Dr. Mark Mouton, M.D
Dr. Mark Mouton, M.D is a Internal Medicine healthcare provider based in Baker, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1164613758.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Mouton, M.D has received a total of $7,918 in payments from pharmaceutical and medical device companies, with $1,351 received in 2024. These payments were reported across 478 transactions from 55 companies. The most common payment nature is "Food and Beverage" ($7,907).
As a Medicare-enrolled provider, Mouton has provided services to 5,910 Medicare beneficiaries, totaling 68,329 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 104 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Location Baker, LA
- Active Since 08/07/2007
- Last Updated 06/29/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1164613758
Products in Payments
- TRELEGY ELLIPTA (Drug) $787.61
- VRAYLAR (Drug) $707.00
- JARDIANCE (Drug) $366.65
- Ozempic (Drug) $291.34
- REXULTI (Drug) $283.13
- TRULICITY (Drug) $281.70
- TRINTELLIX (Drug) $252.82
- NUEDEXTA (Drug) $239.27
- FREESTYLE LIBRE 3 (Device) $236.73
- MOUNJARO (Drug) $164.95
- Veozah (Drug) $161.19
- ENTRESTO (Drug) $158.76
- Aimovig (Biological) $145.81
- RYBELSUS (Drug) $141.53
- QULIPTA (Drug) $133.84
- MYDAYIS (Drug) $131.51
- Kerendia (Drug) $124.75
- EMGALITY (Drug) $119.72
- XARELTO (Drug) $118.68
- AUSTEDO (Drug) $113.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.